February 2023 Br J Cardiol 2023;30:35–8 doi:10.5837/bjc.2023.007
Muntasir Abo Al Hayja, Sobhan Vinjamuri
Introduction Cardiac sarcoidosis (CS) is associated with increased morbidity and mortality.1 Thus, early diagnosis is crucial to introducing immunosuppressive therapy that could prevent an adverse outcome.2 This focused review will discuss the pathology of CS, when to suspect and evaluate CS, and highlight the roles of advanced imaging modalities, i.e. cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) with 18F-Fluorodeoxyglucose/computed tomography (CT) scan (18F-FDG-PET/CT), and their diagnostic and prognostic values in CS in the current content of guidelines for the diagnostic workflow of CS.3 Epidemiology and
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits